Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation reports developments in medical research programs focused on traumatic brain injury, PTSD, suicide ideation, dialysis-borne neuropathy and pruritus. The company’s updates describe its proprietary nasal spray approach for post-head-trauma treatment, its LDX compound, and work with Athena GTX, Athena Telemedicine Partners and scientists at Mississippi State University.
Recurring news also covers Halberd’s NeuroSense AI acquisition and behavioral intelligence platform, which combines multi-modal behavioral data with artificial intelligence for TBI research and clinical assessment. Other company updates address patent-related assets, government-contract efforts, private funding discussions, and OTC public-company communications.
Halberd Corporation has entered an agreement with Mississippi State University to conduct pre-clinical testing of its patent-pending nasal spray aimed at mitigating the effects of Traumatic Brain Injury (TBI). The testing will start on April 10, 2023, and concludes by October 10, 2023. Dr. Russell Carr will oversee the research. Halberd's spray is intended to block the over-production of inflammatory proteins following head trauma, potentially benefiting military personnel and athletes. This initiative underscores Halberd's commitment to addressing neurological complications associated with TBI.
Halberd Corporation (OTC PINK:HALB) announced that it has successfully eradicated all antibiotic-resistant E. coli strains supplied by the CDC ahead of a meeting scheduled for March 29, 2023. Utilizing its patented extracorporeal method combined with metallic nanoparticles, over 90% of the bacteria was eliminated in less than 10 minutes. The company is also testing Klebsiella pneumoniae strains and expects results prior to the CDC meeting. Experts praised the rapid pathogen elimination capabilities, noting minimal adverse effects due to the process being outside the body. Halberd's innovative technology aims to advance therapeutic applications.
Halberd Corporation (OTC PINK:HALB) announced its successful eradication of over 90% of antibiotic-resistant E. coli and Candida auris in under 10 minutes using its patented extracorporeal laser eradication process. With a meeting scheduled with CDC representatives on March 29, 2023, Halberd is set to present these breakthroughs. The technology has already shown success with 12 of the 18 E. coli strains and 4 of the 20 Candida auris strains from the CDC. The company aims to further develop this technology and engage with government agencies and potential partners.
Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eradicating 99.5% of antibiotic-resistant E. coli in vitro within 10 minutes using a patented laser method combined with metallic nanoparticles. This breakthrough, demonstrated with strains provided by the CDC, may revolutionize healthcare by enabling faster treatments and reducing hospitalizations without antibiotics. The ongoing research aims to continue testing and optimizing the technology for commercial application, with intentions to present findings to government agencies.
Halberd Corporation announced a breakthrough in treating Candida auris, a multidrug-resistant fungal pathogen, using a novel extracorporeal method that combines lasers and metallic nanoparticles. This method has shown success in eradicating the fungus in as little as 5 minutes. Dr. Cooper from Youngstown State University emphasized the treatment's potential to mitigate the public health threat posed by such infections. Halberd has also previously demonstrated similar effectiveness against Escherichia coli and antibiotic-resistant bacteria, reinforcing its technology's versatility and potential impact on healthcare costs and patient outcomes.
Halberd Corporation (OTC PINK:HALB) recently showcased its innovative extracorporeal laser eradication process, successfully eliminating antibiotic-resistant bacteria from CDC samples. Conducted at Youngstown State University (YSU), the research led by Professors Dr. Chester Cooper and Dr. W. Gregg Sturrus, emphasizes the effectiveness of their method, which eradicates targeted bacteria in under ten minutes. Halberd's patented technology presents a significant advancement over traditional antibiotic treatments, which often require ten days. The company aims to continue demonstrating the efficacy of its process against various pathogens, potentially revolutionizing future medical treatments.
Halberd Corporation (OTC PINK:HALB) announced animal testing of its patent-pending nasal spray at Mississippi State University to address the effects of Traumatic Brain Injury (TBI). This research follows successful in vitro results in collaboration with Youngstown State University and aims to mitigate TBI-related neurological complications such as PTSD. The triple-action nasal spray can be administered promptly post-injury to potentially reduce long-term damage. Funding for the animal testing program has been secured, with Dr. Russell Carr overseeing the research.
Halberd Corporation (OTC PINK:HALB) has partnered with Mississippi State University to conduct animal testing on novel therapies aimed at mitigating traumatic brain injury effects. The research will be led by the College of Veterinary Medicine and the Department of Biomedical Engineering at the university. Dr. Russell Carr expressed enthusiasm for the collaboration's potential outcomes. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and filed 22 related applications to enhance shareholder value. Further details regarding the testing scope and timeline are expected to follow.
Halberd Corporation (OTC PINK:HALB) made significant strides in the second half of 2022, including a 44.4% enhancement in COVID-19 antibody effectiveness and the establishment of Halberd Cancer Therapeutics, LTD. The company demonstrated control over PD-1, a key cancer protein, and formed strategic alliances to develop longevity treatments. Halberd's monoclonal antibody showed efficacy against antibiotic-resistant bacteria. The firm aims to restore compliance with SEC filing and is pursuing government contracts. Leadership focuses on R&D to secure future partnerships with Big Pharma.
Halberd Corporation (OTC PINK:HALB) has received antibiotic-resistant bacteria (ARB) strains from the CDC for testing its laser eradication technology. Previously reported successes on multiple Gram-Negative bacteria have paved the way for this new phase of testing. The CDC's collaboration emphasizes the potential military applications against bio-weapons. CEO William A. Hartman highlights the significance of this partnership for national safety and the company's interests. Halberd has made strides in intellectual property with multiple patents and pending applications.